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Tobacco smoking is associated with cardiovascular pathology. However, the molecular mech-
anisms of tobacco smoke exposure that lead to initiation or exacerbation of cardiovascular
disease are unclear. In this study, the effects of mainstream tobacco smoke (MTS) on global
transcription in the heart were investigated. Male C57B1/CBA mice were exposed to MTS from
2 cigarettes daily, 5 days/wk for 6 or 12 wk. Mice were sacriﬁced immediately, or 6 wk following
the last cigarette. High-density DNA microarrays were used to characterize global gene expres-
sion changes in whole heart. Fifteen genes were signiﬁcantly differentially expressed following
exposure to MTS. Among these genes, cytochrome P-450 1A1 (Cyp1A1) was upregulated by 12-
fold, and Serpine-1 (plasminogen activator inhibitor-1, PAI-1) was downregulated by 1.7-fold.
Concomitant increase in Cyp1A1 protein levels and decrease in total and active PAI-1 protein
was observed in tissue extracts by Western blot assay and enzyme-linked immunosorbent assay
(ELISA), respectively. Observed changes were transient and were partially reversed during
break periods. Thus, gene expression proﬁling of heart tissue revealed a novel cardiovascular
mechanism operating in response to MTS. Our results suggest a potential role for PAI-1 in
MTS-induced cardiovascular pathology.
Tobacco smoking remains the second largest preventable
causeofmortalityandmorbidityworldwide(Proctor,2004).Ex-
posure to tobacco smoke causes coronary disease (Price et al.,
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1999), atherosclerosis (Chen et al., 1995), and ischemic heart
disease (Njolstad et al., 1996). The degree of this risk is pro-
portional to the amount of smoking (Sherman, 1991). While the
chemical properties of tobacco smoke are relatively well char-
acterized, the mechanisms by which smoking leads to disease
andthefactorsthatdeterminesusceptibilitytothesediseasesare
not well understood.
The interaction between cigarette smoke and the cardiovas-
cular system involves complex molecular pathways that are not
clearly elucidated. The use of DNA microarrays enables the
simultaneous monitoring of thousands of transcripts in a single
experimentandcanbeusedtounderstandcomplexmolecularre-
sponses.Inthepresentstudy,weusedAgilenthigh-densityDNA
microrrays to examine global transcriptional changes in heartREPRESSION OF PLASMINOGEN ACTIVATOR INHIBITOR-1 79
tissue of mice exposed to mainstream tobacco smoke (MTS) for
6o r1 2wk, respectively. Our ﬁndings reveal the repression of
plasminogenactivatorinhibitor1(PAI-1),akeygeneinvolvedin
ﬁbrinolysis, in the hearts of mice exposed to MTS. This ﬁnding
is in contrast to established evidence demonstrating an increase
in plasma PAI-1 activity and impaired ﬁbrinolysis in cardiovas-
cular diseases (Gils & Declerck, 2004; Hamsten et al., 1987;
Juhan-Vague et al., 1987; Vaughan, 2005). We suggest a poten-
tialnonﬁbrinolyticroleforPAI-1followingprolongedexposure
to MTS.
MATERIALS AND METHODS
Animal Care and Husbandry
Twenty mature (8–10 wk old) male C57BL/6 × CBA F1
hybrid mice (Jackson Laboratory) were exposed to MTS (Yauk
etal.,2007)usingasmokeexposuresystem(Simanietal.,1974)
adapted for mice (Hautamaki et al., 1997). Brieﬂy, mice in in-
dividual exposure chambers were exposed to 2 cigarettes daily
(1R3 reference cigarettes; Tobacco and Health Research Insti-
tute, University of Kentucky) at a rate of 0.08 L/min, 1 (20-ml)
puff per 52 s, 5 days/wk for a total of 6 wk or 12 wk, includ-
ing the 2-wk lead-up period (Yauk et al., 2007). Control mice
were placed in restrainers only. Animals were anesthetized with
isoﬂurane and euthanized by exsanguation. Animal procedures
were carried out under the guidelines of the Canadian Coun-
cil on Animal Care and procedures approved by the McMaster
University Animal Research Ethics Board.
Tissue Processing
Whole hearts were excised from the mice, snap-frozen in
liquid nitrogen and stored at –80◦C. At the time of experiment,
frozen heart tissue was sliced randomly into two (upper and
lower) halves. The upper half was used for RNA extraction. The
lowerhalfwasfurtherdividedintwosectionsrandomlyfortotal
protein extracts and microsome preparation.
RNA Extraction and Puriﬁcation
Frozenhearttissuewasslicedasdescribedearlier.TotalRNA
was isolated from the upper portion of the heart tissue using
TRIzolreagent(Invitrogen)andpuriﬁedusingRNeasyMiniKit
(Qiagen). All RNA samples showed A260/280 ratios between
2.0 and 2.1. RNA integrity was determined using an Agilent
2100 Bioanalyzer (Agilent Technologies) and only high-quality
RNA (28S/18S > 1.8) was used for further analysis.
Microarray Hybridization
Individualtotal(2.5µg)RNAsamplesofhearttissuefrom40
mice (5 mice for each group, 4 treatment groups and 4 control
groups) and universal reference total RNA (Stratagene) were
used to synthesize double-stranded cDNA and cyanine-labeled
cRNA (samples with Cyanine 5-CTP, and reference RNA with
Cyanine 3-CTP, Perkin-Elmer Life Sciences) according to the
manufacturer’s instructions (Agilent linear ampliﬁcation kits,
Agilent Technologies). Cyanine-labeled cRNA targets were in
vitro transcribed using T7 RNA polymerase and puriﬁed by
RNeasy Mini Kit (Qiagen). Five micrograms of each labeled
cRNA was hybridized to Agilent 4121A oligonucleotide mi-
croarrays(AgilentTechnologies)at60◦Covernight.Arrayswere
washedandscannedonaScanArrayExpress(Perkin-ElmerLife
Sciences), and data were acquired with ImaGene 5.5 (BioDis-
covery).
Statistical Analysis of Microarray Data
Abalancedblockedfactorialdesign(Montgomery,2001)us-
ing the date of hybridization and the date of exposure (Kerr,
2003)wasusedtoanalyzetheheartdata.Thedatawerenormal-
izedusingalowesscurve(Yangetal.,2002)usingtheSAS/STAT
software, Version 8.2 of the SAS System for Windows (1999–
2001, SAS Institute, Inc.). Ratio intensity plots and heat maps
for the raw and normalized data were constructed using R (R
Development Core Team, 2005).
Differentially expressed genes between the control and
treated groups within time points were determined using the
MAANOVA library (Wu et al., 2003) in R. The main effects in
the model included treatment, duration of exposure, and break
period, as well as all two-way interactions and the three-way
interaction. This model was applied to the log2 of the relative
intensities. The Fs statistic (Cui et al., 2005), a shrinkage esti-
mator for the gene-speciﬁc variance components, was used to
test main effects, interactions, and pairwise comparisons. The p
valuesforallthestatisticaltestswereestimatedusingthepermu-
tationmethodusingresidualshufﬂing.These p valueswerethen
adjusted for multiple comparisons by using the false discovery
rate (FDR) approach (Benjamini, 1995).
The group means for the fold change calculation were based
on the adjusted relative intensity for each gene where the esti-
mated day of hybridization and date of exposure effects using
parameter estimates from the analysis of variance (ANOVA)
model were subtracted from the normalized ratio.
Real-Time Reverse-Transcription Polymerase Chain
Reaction (RT-PCR)
Primers were designed using Beacon design 2.0 (Premier
BioSoft International). About 2.5 µgo ftotal RNA per sample
wasr everse transcribed and quantitative polymerase chain
reaction (PCR) was performed in duplicate with an iCycler IQ
real-timedetectionsystem(Bio-Rad)asdescribedinDongetal.
(2005). The values of the threshold cycle were averaged. Gene
expression levels were normalized to the ubiquitin gene. PCR
efﬁciencywasexaminedusingthestandardcurveforeachgene.
Primer speciﬁcity was assured by the melting curve for each
gene. A t-test was used for statistical evaluation. Primer pairs
used were: PAI-1 forward 5 CCCACACAGCCCATCAGG 3 ,
PAI-1 reverse 5  CCGAGGACACGCCATAGG 3 , Ubc forward
5 ACCTTCCTCACCACAGTATC 3 , Ubc reverse 5 CCATC
ACACCCAAGAACAAG 3 , Cyr61 forward 5 GTTCCGAT
GCGAAGATGG 3 , Cyr61 reverse 5 CTTGTGGATGT80 S. HALAPPANAVAR ET AL.
CATTGAATAGG 3  Cyp1A1 forward 5 ATTCCTGTCCTCCG
TTACC 3 , Cyp1A1 reverse 5 AGGCTGTCTGTGATGTCC 3 .
Preparation of Microsomes
A section of the heart was taken from ﬁve individual mice
(n = 5/treatment group). These heart sections were pooled
into one sample. Approximately 1.0 g heart was homogenized
in 2.5 ml ice-cold homogenization buffer containing 0.05 M
Tris and 1.15% KCl, pH 7.4, using an ice-cold grinding vessel
(size C, Thomas Scientiﬁc). The heart homogenates were cen-
trifugedat10,000×g(9000rpm)for20minat4◦C.Supernatant
was then centrifuged 176,000 × g (44,000 rpm) for 1 h (rotor
Ty 70.1, Beckman Ultracentrifuge). The supernatant was de-
canted, and 0.25 M sucrose was added to the microsomal pellet.
The pellet was dispersed by brief sonication and was quanti-
ﬁed for total protein content using a Bradford protein assay kit
(Bio-Rad).
Preparation of Tissue Protein Extracts and Western
Blotting
Aportionofthefrozenheartwashomogenizedinlysisbuffer
(5 M HEPES, pH 7.5, 5 M NaCl, 10% glycerol, 1% Triton X-
100, 2 M EGTA, 1 M MgCl2, 0.5 M NaF, 0.2 M sodium py-
rophosphate, and protease inhibitor cocktail tablets [Roche Ap-
plied Science]), centrifuged, and the supernatant was quantiﬁed
forproteincontentusingaBradfordproteinassaykit(Bio-Rad).
Approximately 200 µgo ftotal protein was extracted from each
individual mouse (n = 5/treatment group) from one treatment
group, and subsequently pooled to make one sample. The pro-
tein content of each pooled sample was quantiﬁed again using a
Bradford protein assay kit.
ForW estern blotting, 30 µg total protein (pooled) or 50 µg
microsomalextractwasimmunoblottedon8–12%sodiumdode-
cylsulfatepolyacrylamidegelelectrophoresis(SDS-PAGE)gels
and analyzed using antibodies against PAI-1, Cyp1A1 (Santa
Cruz Biotechnologies), and tPA (American Diagnostica). Sig-
nals were detected by ECL Plus (GE Health Sciences).
Total PAI-1 Antigen and Activity Assay
Murine total PAI-1 antigen and activity assay kits (Innova-
tion Research, Inc.) were used to analyze total and active PAI-1
protein present in heart tissue extracts. All incubations were
carried out at room temperature for 30 min with agitation at
300 rpm. Fifty micrograms of pooled protein extracts for total
and 100 µg for active PAI-1 determination in triplicates along
with known amounts of PAI-1 standards in duplicates were as-
sayed on a 96-well plate coated with capture antibody or uroki-
nase, respectively. Unbound PAI-1 was washed and the plate
was reacted ﬁrst with anti PAI-1 primary antibody followed by
horseradish secondary antibody. Wells were then reacted with
TMB substrate solution for 7 min and reactions were quenched
with the addition of 1 N H2SO4. The absorbance was measured
at 450 nm on a microtiter plate spectrophotometer.
Tissue Plasminogen Activator (tPA) Activity Assay
Mouse tissue plasminogen activator (tPA) activity assay kit
(Innovation Research, Inc.) was used to quantify the active
mouse tPA in the tissue extracts of heart. All the reactions
were carried out at ambient temperature on a shaker at 300 rpm
for 30 min. In brief, 96-well immulon strip plates coated with
Avidin were reacted with biotinylated human PAI-1. A series of
knownconcentrationsoftPAactivitystandardsinduplicatesand
100 µg pooled total protein extracts in triplicates were added to
the wells. Wells were incubated with primary anti murine-tPA
antibody,horseradishperoxidaseconjugatesecondaryantibody,
and ﬁnally with TMB substrate. The reaction was quenched by
theadditionof1 N H2SO4.Finalabsorbancewasreadat450 nm
5 min after the addition of H2SO4.
RESULTS
Global Transcriptional Proﬁling
Complete DNA microarray data are available in ArrayEx-
press (http://www.ebi.ac.uk/microarray-as/aer/?#ae-main, ac-
cession number E-MEXP-1553). Approximately 85% of the
22,000transcriptsonthearraywereexpressed(whereexpressed
is deﬁned as at least 4 out of 5 samples with signal intensities
above background in at least 1 experimental condition). Dif-
ferentially expressed genes were identiﬁed using MAANOVA;
values were considered signiﬁcantly different from control val-
ues when the FDR adjusted p value was less than .05.
Differential gene expression was identiﬁed for 15 genes in
the smoke-exposed group (Table 1; 4 upregulated and 11 down-
regulatedbyatleast1.2-to1.5-foldcomparedtoshamcontrols).
The largest change was observed in Cyp1A1, with 12-fold and
8-fold increases in gene expression at 6 and 12 wk, respectively.
Serpine1 (PAI-1) and Cyr61 were downregulated with 1.7- and
1.9-fold repression, respectively. Others include suppression of
Lpin3,acandidategeneforhumanlipodystrophy(Peterfyetal.,
2001);Kpna2(Umegakietal.,2007),animportin;andAKAP12,
a tumor suppressor (Flotho et al., 2007). However, changes in
geneexpressionweretransientandwerepartiallyreversedwhen
smoking was discontinued (Table 1, columns B and D).
Real time RT-PCR was performed to measure the expres-
sion levels of select genes on the same RNA samples used for
microarray analysis (Figure 1). Results conﬁrmed the upregula-
tion of Cyp1A1, and downregulation of PAI-1 and Cyr61 in 6-
and 12-wk smoke-exposed samples. The observed fold changes
by real-time RT-PCR were much higher than those measured
by DNA microarrays (Wang et al., 2006). In keeping with the
microarray results, changes were partially reversed following
smoking cessation. Gene expression changes for these genes
were also conﬁrmed by RT-PCR in heart tissues of female mice
identically exposed to MTS (data not shown).
Increased Cyp1A1 Protein Levels in Heart Microsomes
Benzo[a]pyrene (BaP), a carcinogenic polycyclic aromatic
hydrocarbon (PAH) found in tobacco smoke, is metabolicallyREPRESSION OF PLASMINOGEN ACTIVATOR INHIBITOR-1 81
TABLE 1
List of genes up or down regulated in the treatment groups
Description (Mus musculus mRNA) Fold change
1234
Cytochrome P-450, family 1,
subfamily a, polypeptide 1
(Cyp1a1)
11.7 1.3 8.2 –1.0
Cysteine-rich protein 61 (Cyr61) –1.9 –1.3 –1.1 –1.4
RIKEN cDNA 1300002F13 gene
(1300002F13Rik)
–1.8 –1.4 –1.0 –1.3
H2A histone family, member Y
(H2afy)
1.8 –1.2 1.1 1.0
Serine (or cysteine) proteinase
inhibitor, clade E, member 1
(Serpine1)
–1.7 –1.5 –1.3 –1.5
DNA segment, Chr 4, expressed
(D4Wsu53e)
1.6 1.1 1.2 1.1
Basic helix–loop–helix domain
containing, class B2 (Bhlhb2)
–1.5 –1.2 –1.1 –1.2
Karyopherin (importin) alpha 2
(Kpna2)
1.5 1.1 1.0 1.0
Small proline-rich protein 1A
(Sprr1a)
–1.5 1.2 –1.0 –1.2
Lipin 3 (Lpin3) –1.4 1.2 –1.0 –1.1
Colony-stimulating factor 1
(macrophage) (Csf1)
–1.4 1.0 –1.1 –1.0
Unknown –1.3 1.1 1.0 –1.1
A kinase (PRKA) anchor protein
(gravin) 12 (Akap12)
–1.3 1.0 –1.0 –1.1
Carbamoyl-phosphate synthetase 1 –1.1 –1.3 1.3 1.3
RIKEN cDNA 4632404H22 gene
(4632404H22Rik)
–1.2 –1.2 1.3 –1.1
Note.Foldinductionovermatchedcontrolsfortreatmentgroups:1,
6w ksmoke; 2, 6 wk smoke followed by 6 wk break; 3, 12 wk smoke;
4, 12 wk smoke followed by 6 wk break. Negative values indicate
downregulated genes.
activated by genes in the cytochrome P-450 family. It is pre-
dicted that if BaP is metabolized in the vessel wall of the heart
tissue, the initial event should be the induction of Cyp1A1 (the
main form of the Cyp genes responsible for BaP metabolism
in the heart) (Thirman et al., 1994). After exposure to 6 and
12 wk of MTS, heart microsomes showed distinct immunore-
active bands for Cyp1A1 (Figure 2). Similar to transcriptional
induction,Cyp1A1proteinsynthesisinsmoke-exposedanimals
was highly induced compared to their matched controls, and
protein levels returned to normal following the break periods.
PAI-1 Protein Abundance and Activity
Increased plasma levels of PAI-1 expression have rou-
tinely been found in many cardiovascular diseases (Dellas &
Loskutoff, 2005). The present study is the ﬁrst to show in vivo
repression of PAI-1 in response to toxicant exposure, such as
MTS. In order to verify that changes in mRNA levels of PAI-
1 result in inhibition or decrease in its protein levels in heart,
known amounts of cellular protein from whole heart tissue ex-
tract were assayed by Western blot as well as by enzyme-linked
immunosorbentassay(ELISA).ReductionintotalPAI-1protein
was not evident by Western blotting (data not shown). However,
signiﬁcant reduction (40%) in total PAI-1 protein was observed
following 6 wk of MTS exposure using the total PAI-1 antigen
assay (Figure 3A). Although PAI-1 levels (mRNA expression)
showed marginal recovery after 12 wk of MTS exposure, total
proteinwasstill20%lessthanthecontrols.PAI-1levelsreturned
to normal during the break periods.
TotalactivePAI-1wasalsomeasuredinwholetissueextracts.
Consistent with our protein analysis, at 6 wk after MTS expo-
sure,activePAI-1levelswerelessthan0.5-foldoftheirmatched
controls.Interestingly,levelsofactivePAI-1proteinincreased2-
fold after 12 wk of exposure (Figure 3B). As mRNA expression
andtotalproteinlevelsofPAI-1duringthebreakperiodsdidnot
change, we did not measure the active levels of PAI-1 in these
samples. To investigate additional effects of PAI-1 downregu-
lation, we examined total cellular tPA levels. Transcriptional
repression of PAI-1 in response to MTS exposure did not af-
fect total tPA protein levels (Figure 4A). We also quantiﬁed the
total active tPA in heart tissues using a Murine tPA activity im-
munoassay. Although we saw a corresponding change in total
active tPA (Figure 4B) with decreasing PAI-1 levels at 6 and
12 wk (Figure 3A) following MTS exposure, results were not
statistically signiﬁcant.
DISCUSSION
Global analysis of gene expression in the hearts of mice ex-
posed to MTS revealed surprisingly few genes exhibiting dif-
ferential expression. Upregulation of Cyp1A1 conﬁrmed that
chemical constituents of the tobacco smoke reached the heart,
and that changes in transcripts could be measured (Figure 1).
Fifteen genes were differentially expressed as a result of the
exposure, of which 3 (cytochrome P-450 1A1 subfamily a,
polypeptide 1, cysteine-rich protein 61, and serine [or cysteine]
proteinase inhibitor, clade E, member 1 [PAI-1]) were respon-
sive at both the 6- and 12-wk time points (Table 1). The re-
sponsive genes were found to be involved in pathways related
to xenobiotic metabolism and ﬁbrinolysis. There is a strong re-
lationship between cigarette smoking, ﬁbrinolytic mechanisms,
and elevated risk for cardiovascular events. Components of the
ﬁbrinolysis pathway—endothelium, platelets, and ﬁbrinogen—
are inﬂuenced by active smoking. Smoking causes endothelial
dysfunctionandimpairsacuteendogenousﬁbrinolyticcapacity,
a mechanism by which cigarette smoking can result in arterial
thrombosisandmyocardialinfarction(MI)(Newbyetal.,1999).
Intriguingly, PAI-1, a key inhibitor of tissue type and uroki-
nase plasminogen activator in plasma, was downregulated in
the mice exposed to MTS at both time points. PAI-1 is an
acute-phase response gene and its levels in plasma are tightly82 S. HALAPPANAVAR ET AL.
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FIG. 1. Validation of microarray results. Data are presented as fold change over control values (n = 5 mice/group, ± SEM): 1,
6w ksmoke; 2, 6 wk smoke + 6w kbreak; 3, 12 wk smoke; and 4, 12 wk smoke + 6w kbreak. Asterisk indicates signiﬁcant at
p < .05, t-test conducted on RT-PCR values.
FIG. 2. Cyp1A1 protein abundance in heart microsome extract (n = 5). MW: molecular weight marker; +ve control: BaP-treated
lung microsome extract. Lanes 1–4: treatment groups, 6 wk smoke, 12 wk smoke, 6 wk smoke + 6w kbreak, and 12 wk smoke
+ 6w kbreak; lanes 5–8: matched controls.
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FIG. 3. (A) Total immunoreactive PAI-1 in heart tissue extracts. (B) PAI-1 activity in heart tissue extracts. Data represent fold
change over matched controls (n = 5, ± SEM): 1, 6 wk smoke; 2, 6 wk smoke + 6w kbreak; 3, 12 wk smoke; 4, 12 wk smoke +
6w kbreak.REPRESSION OF PLASMINOGEN ACTIVATOR INHIBITOR-1 83
FIG. 4. (A) Western blot of immunoreactive tPA in heart tissue extracts. Lanes 1, 3, 5, and 7 represent 6 wk smoke, 6 wk smoke +
6w kbreak, 12 wk smoke, and 12 wk smoke + 6w ksmoke. Lanes 2, 4, 6, and 8 represent matched controls. (B) Total tPA activity
present in heart tissue extracts. Data shown as fold change over matched controls:1, 6 wk smoke; 2, 6 wk smoke + 6w kbreak; 3,
12 wk smoke; 4, 12 wk smoke + 6w kbreak.
regulatedbylocalcellularenvironment(Kluftetal.,1985;Dellas
& Loskutoff, 2005; Sawdey & Loskutoff, 1991). High levels of
circulatingPAI-1contributetothedevelopmentofMI,coronary
artery disease, and pathologic thrombosis (Dellas & Loskutoff,
2005;Gils&Declerck,2004;Hamstenetal.,1987;Juhan-Vague
et al., 1987; Vaughan, 2005), worsen the prognosis of patients
suffering from MI, and are routinely observed in atherosclerotic
plaques,macrophages,andendothelialcellsofpeoplediagnosed
with cardiac diseases (Schneiderman et al., 1992). Thus, the re-
lationshipofincreasedplasmaPAI-1activityandcardiovascular
disease incidence is well documented. However, a direct causal
relationship between increased PAI-1 expression and a known
cardiac disease is yet to be established. Moreover, PAI-1 knock-
out mice are phenotypically normal, although they are more
prone to bleeding when challenged (Carmeliet et al., 1993a,
1993b) . Deﬁciency or total absence of PAI-1 expression in hu-
mans is associated with mild atypical bleeding diathesis and
no apparent disease state (Agren et al., 2007; Santamaria et al.,
2007). These studies raise important questions about the impli-
cations of altered PAI-1 expression in these disease models.
Our ﬁnding of downregulation of PAI-1 mRNA and protein
synthesis in heart tissue of mice exposed to 6 and 12 wk of MTS
is consistent with previous work on plasma PAI-1 levels in hu-
mansexaminingacuteeffectsofsmokinginchronicsmokersand
nonsmokers.TheauthorsfounddecreasedplasmalevelsofPAI-
1i nchronic smokers compared to nonsmokers within 30 min of
both groups smoking 2 cigarettes (Ozdemir et al., 1992). They
suggested that platelets and endothelial cells of nonsmokers are
more sensitive to acute smoking than those of chronic smokers,
andthatchronicsmokingcausesreceptordownregulationorex-
haustion of the platelets and endothelial cells (Ozdemir et al.,
1992). Our results demonstrate that the transcriptional down-
regulation of PAI-1 mRNA leads to decreased protein synthesis
in whole heart tissue in mice. This ﬁnding, likely attributed to
endothelial cell response, is a potential mechanism for the ob-
served decrease in plasma PAI-1 levels measured by Ozdemir et
al.(1992)inchronicsmokers.TotalcellularPAI-1ismuchlower
thansecretedlevels.ItisthefreecirculatingPAI-1inplasmathat
is capable of binding tPA and inactivating ﬁbrinolysis. The dra-
matic decrease in total protein synthesized (Figure 3A) at 6 wk
following MTS was accompanied and further validated by ob-
served differences in active PAI-1 levels (Figure 3B). Although
Furuyama et al. (2006) noted that in RHMVE cells exposed
to diesel exhaust particles, only secreted PAI-1, not total cellu-
lar PAI-1, levels decreased with decreasing mRNA (Furuyama
et al.,2006),wedidseeafairlysigniﬁcantchangeinactivePAI-
1l evels in heart tissue extracts. The discrepancy could be due
to differences in the type of cells and chemicals used, or as a
result of differences in response of cultured monolayer of cells
comapred to whole heart tissue. Future work will investigate
PAI-1 levels in plasma.
Growth factors, cytokines, and hormones involved in inﬂam-
mation and tissue remodeling induce PAI-1 expression (Loskut-
off et al., 1989). Transforming growth factor (TGF) β1i sama-
jor regulator of PAI-1 in both in vivo and in vitro models (Dong
etal.,1996).Oxidativestress(Furuyamaetal.,2006)andMAPK
signaling pathways (Pasten et al., 2007) are shown to downreg-
ulate PAI-1 mRNA expression in vitro. Our microarray results
demonstrate downregulation of KPNA2 (Table 1), an importin
regulated by TGFβ1 pathway (Umegaki et al., 2007). RT-PCR
results show signiﬁcant downregulation of an acute response
gene JunB mRNA, a downstream target of TGFβ1, and a small
decrease in cytokine TGFβ1, its receptor TGFR2, following
6w ko fe xposure to MTS (data not shown). Therefore, we spec-
ulateoverallshutdownofacuteresponsetoMTSinheartat6 wk
following exposure to MTS.
Interestingly,wealsofoundasmallincreaseinPAI-1mRNA
expression (relative to 6 wk) and protein levels at 12 wk after
MTS exposure (Figures 1 and 3A). An increase in blood serum
and bronchoalveolar lavage ﬂuid counts for total cell number
and mononuclear cells was also observed, accompanied by an
increase in interleukin (IL)-6 mRNA and protein expression in
lungsofthe12-wkMTSanimals(unpublisheddata).Thesedata
demonstrate potential initiation of inﬂammatory response with84 S. HALAPPANAVAR ET AL.
continuing exposure to MTS. Apart from its role in stabilizing
a ﬁbrin clot, PAI-1 is also implicated in inﬂammation, wound
healing, and tissue repair. Vascular events including inﬂamma-
tion and tissue injury increase with chronic smoking and thus
may necessitate reversal of PAI-1 expression. However, altered
PAI-1 gene expression or protein synthesis resulted in subtle
and nonsigniﬁcant changes in overall tPA levels and its activity
(Figure 4).
Thus, time-dependent changes in PAI-1 expression and re-
versal of its repression during quit periods suggest tight regu-
lation of PAI-1 expression and suggest separate functions for
PAI-1 in response to different MTS exposure scenarios. Studies
have shown that downregulation of PAI-1 reduces cardiomy-
ocyte apoptosis after acute MI (Xiang et al., 2005). Red wine
polyphenols offer cardioprotection associated with decreasing
PAI-1 expression in human coronary artery endothelial cells
(Pasten et al., 2007). We hypothesize that transient PAI-1 re-
pression after an acute event such as exposure to MTS is cardio
protective and may involve nonﬁbrinolytic functions of PAI-1.
AnobservedincreaseinPAI-1atalaterstagemaybeapotential
risk factor for developing a cardiac event.
In summary, we investigated global gene expression proﬁles
of heart tissue of mice exposed chronically to MTS, and fol-
lowing smoking cessation. We demonstrate transcriptional re-
pression and decreased protein abundance of PAI-1 in whole
heart tissue of mice exposed to MTS. Importantly, the results
suggest that individual susceptibility to the development of car-
diac disease in smokers may depend on early events, including
PAI-1 regulation. Future work will examine the manifestation
of cardiac disease in PAI-1 knockout mice exposed to MTS.
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